TriangleUbamatamab (NCT06787612)
Ubamatamab trial for Ovarian Cancer (NCT06787612). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with advanced platinum-resistant serous or endometrioid ovarian, fallopian-tube or primary peritoneal cancer, with measurable progression after prior therapy.
The idea: ubamatamab connects T cells to MUC16 on cancer cells. Randomly assigned groups receive ubamatamab with sarilumab; some groups also receive bevacizumab, cemiplimab plus fianlimab, pegylated liposomal doxorubicin, or REGN10597. Researchers measure tumor responses, side effects and drug levels. Doses and schedules are not published in the record.
This phase 2 study plans 297 patients. Regeneron sponsors it; 21 US sites are recruiting, including Birmingham.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.